Search results for "health care model"

showing 2 items of 2 documents

Management of Oral Anti-Coagulation in Patients with Heart Failure-Insights from the ThrombEVAL Study

2018

AbstractPatients with heart failure (HF) are frequently anti-coagulated with vitamin K-antagonists (VKAs). The use of long-acting VKA may be preferable for HF patients due to higher stability of plasma concentrations. However, evidence on phenprocoumon-based oral anti-coagulation (OAC) therapy in HF is scarce. The aim of this study was to assess the impact of the presence of HF on quality of phenprocoumon-based OAC and the subsequent clinical outcome. Quality of OAC therapy and the incidence of adverse events were analysed in a cohort of regular care (n = 2,011) from the multi-centre thrombEVAL study program (NCT01809015) stratified by the presence of HF. To assess the modifiability of outc…

MaleAdministration Oralheart failureclinical outcomeED AMERICAN-COLLEGE030204 cardiovascular system & hematologyTHERAPY ANTITHROMBOTIC THERAPYCohort StudiesPhenprocoumon0302 clinical medicinequality of careGermanyProspective Studies030212 general & internal medicineProspective cohort studyAged 80 and overOUTCOMESIncidenceHazard ratioHematologyTreatment OutcomeCohortFemaleCLINICAL-PRACTICE GUIDELINESSINUS RHYTHMmedicine.drugCohort studyRiskmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsHemorrhageWARFARINEJECTION FRACTION03 medical and health sciencesInternal medicinemedicineHumansAdverse effectAgedbusiness.industryWarfarinhealth care modelAnticoagulantsmedicine.diseaseoral anti-coagulationHeart failureATRIAL-FIBRILLATIONPhenprocoumonADVERSE EVENTSbusinessANTICOAGULANT-THERAPY
researchProduct

Sicily Network for Liver Cancer: A Multidisciplinary Network Model for the Management of Primary Liver Tumors

2020

Background: The management of primary liver tumors requires the involvement of multiple specialist skills and the best possible treatment in terms of cost, risk, and benefit that could be provided by hepatobiliary or transplant surgeon, interventional radiologist, hepatologist, radiotherapist, or oncologist is needed to be chosen for each patient. This is particularly relevant for hepatocellular carcinoma (HCC), that is the most common primary liver tumor, and it occurs in more than 90% of cases in the setting of cirrhosis. Methods: To address the increasing complexity of cancer care, multidisciplinary tumor boards (MDTBs) have evolved to offer patients appropriate and tailored cancer treat…

Liver Cirrhosismedicine.medical_specialtyCirrhosisLiver tumorCarcinoma HepatocellularLiver Cirrhosicancer treatmentliver cancerMultidisciplinary approachHealth caremedicineHumansIntensive care medicineSicilyPatient Care Teambusiness.industryLiver Neoplasmshealth care modelCancerhepatocellular carcinomamedicine.diseaseSurgeryhealth care modelsLiver NeoplasmSicily.Hepatocellular carcinomanetworkSurgeryTransplant surgeonLiver cancerbusinesscholangiocarcinomaDelivery of Health CaremultidisciplinaryHuman
researchProduct